Table 9.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Liver Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 3,934 4,081 4,185 4,516 4,751 4,989 5,188 5,331 5,671 6,168
With Immunosuppression Info 3,389 3,528 3,867 4,199 4,435 4,841 5,026 5,198 5,520 5,923
Induction Drugs 2.9% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 4.5% 3.7% 2.1% 1.2% 0.7% 0.7% 0.4% 0.5% 0.5% 0.4%
OKT3 10.1% 6.7% 4.9% 3.6% 1.4% 0.8% 0.7% 0.3% 0.3% 0.2%
Thymoglobulin 0.0% 0.0% 0.0% 0.1% 0.5% 1.2% 2.4% 4.2% 6.5% 7.4%
Zenapax 0.0% 0.0% 0.0% 2.9% 6.6% 6.6% 5.8% 4.6% 5.6% 4.7%
Simulect 0.0% 0.0% 0.1% 1.4% 4.4% 6.6% 6.2% 7.8% 7.2% 6.3%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 1.6%
No Induction Drugs Recorded 82.8% 89.6% 92.9% 91.0% 86.7% 84.5% 84.6% 82.7% 79.5% 79.5%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.